Overview

Statin Therapy in Patients With Early Stage ADPKD

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study plans to learn if pravastatin is helpful in slowing down the progression of kidney disease in adults with autosomal dominant polycystic kidney disease (ADPKD). Pravastatin has been approved by the Food and Drug Administration (FDA) for adults for treatment of hyperlipidemia (high cholesterol levels). The investigators are using pravastatin in this study as an investigational drug for treatment of ADPKD.
Phase:
Phase 4
Details
Lead Sponsor:
University of Colorado, Denver
Treatments:
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pravastatin